Chen Liang is a Professor of Medicine at McGill University, a
Senior Investigator at the Lady Davis Institute of Jewish General Hospital, and
the Director of McGill Centre for Viral Diseases. He obtained both his BSc and
Ph.D. (Molecular Biology) at Nankai University in China, after which he came to
McGill for post-doctoral studies at the Lady Davis Institute. In 1999, he was
named Assistant Professor in McGill’s Department of Medicine, and in 2017, he
was made Full Professor. From 2011 to 2019, he was an Associate Director for
Faculty Development at the Lady Davis Institute. His research interests focus
on understanding the infection and pathogenesis of highly pathogenic human
viruses. His group uses molecular, genomic, and proteomic approaches to decipher
the complex interactions between viruses and hosts, with a focus on the
antiviral innate immune responses to pathogenic RNA viruses, including HIV-1 and
SARS-CoV-2. He has pioneered the application of the CRISPR gene editing
technology in curing HIV-1-infected cells by cleaving and eliminating the
integrated viral DNA. His group is dedicated to the understanding of the
dysregulated interferon and inflammatory cytokine responses in
SARS-CoV-2-infected individuals.
Research Keywords & Expertise
antivirals
Interferon
HIV (human immunodefic...
Innate immunity and in...
SARs- CoV- 2
Fingerprints
32%
antivirals
32%
Interferon
7%
Innate immunity and inflammation
5%
HIV (human immunodeficiency virus)
Short Biography
Chen Liang is a Professor of Medicine at McGill University, a
Senior Investigator at the Lady Davis Institute of Jewish General Hospital, and
the Director of McGill Centre for Viral Diseases. He obtained both his BSc and
Ph.D. (Molecular Biology) at Nankai University in China, after which he came to
McGill for post-doctoral studies at the Lady Davis Institute. In 1999, he was
named Assistant Professor in McGill’s Department of Medicine, and in 2017, he
was made Full Professor. From 2011 to 2019, he was an Associate Director for
Faculty Development at the Lady Davis Institute. His research interests focus
on understanding the infection and pathogenesis of highly pathogenic human
viruses. His group uses molecular, genomic, and proteomic approaches to decipher
the complex interactions between viruses and hosts, with a focus on the
antiviral innate immune responses to pathogenic RNA viruses, including HIV-1 and
SARS-CoV-2. He has pioneered the application of the CRISPR gene editing
technology in curing HIV-1-infected cells by cleaving and eliminating the
integrated viral DNA. His group is dedicated to the understanding of the
dysregulated interferon and inflammatory cytokine responses in
SARS-CoV-2-infected individuals.